Cholesterol drug setback casts doubt over multibillion-dollar race

Novartis' pelacarsen failed to reduce cardiovascular events despite lowering the harmful cholesterol Lp(a). The setback raises uncertainty for rival experimental Lp(a) drugs from Amgen and Eli Lilly.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。